Production (Stage)
Pasithea Therapeutics Corp.
KTTA
$0.69
$0.00070.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.92% | -2.65% | -34.25% | -11.85% | 8.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.94% | -36.69% | -20.71% | 3.04% | 25.78% |
| Operating Income | 8.94% | 36.69% | 20.71% | -3.04% | -25.78% |
| Income Before Tax | 7.71% | 36.84% | 16.96% | -7.45% | -18.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.71% | 36.84% | 16.96% | -7.45% | -18.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.71% | 37.05% | 16.96% | -2.74% | -9.13% |
| EBIT | 8.94% | 36.69% | 20.71% | -3.04% | -25.78% |
| EBITDA | 9.30% | 37.89% | 21.64% | -3.17% | -27.13% |
| EPS Basic | 56.49% | 44.30% | -0.05% | -28.64% | -36.47% |
| Normalized Basic EPS | 56.50% | 43.91% | -0.05% | -34.55% | -47.84% |
| EPS Diluted | 56.49% | 44.30% | -0.05% | -28.64% | -36.47% |
| Normalized Diluted EPS | 56.50% | 43.91% | -0.05% | -34.55% | -47.84% |
| Average Basic Shares Outstanding | 112.11% | 2.27% | -17.01% | -20.14% | -20.04% |
| Average Diluted Shares Outstanding | 112.11% | 2.27% | -17.01% | -20.14% | -20.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |